Ketamine vs. EMDR for Anxiety: Which Treatment Works Best?

Quick Summary

Eye Movement Desensitization and Reprocessing (EMDR) has a well-established evidence base for treating PTSD. It has limited and methodologically constrained evidence specifically for anxiety disorders.

Ketamine therapy has peer-reviewed real-world effectiveness data for anxiety at a highly meaningful scale. Neither modality has been compared head-to-head in an RCT for anxiety.

The sections below break down these differences to help guide your decision.

What Is Ketamine Therapy?

Ketamine is a medication that has been FDA-approved as an anesthetic since 1970. It has been included on the World Health Organization List of Essential Medicines since 1985.¹

Licensed providers prescribe ketamine off-label in sub-anesthetic, provider-determined doses for anxiety, depression, PTSD, and related conditions. Off-label prescribing is a standard, legally accepted medical practice that accounts for a substantial percentage of all psychiatric prescriptions.²

Ketamine temporarily modulates glutamate signaling and NMDA receptor activity in the brain.³ Because it works through these pathways, the medication supports synaptogenesis and neuroplasticity.

The resulting neuroplastic window allows entrenched thought patterns and anxiety responses to shift. Sessions take place in a supervised setting, with effects beginning within minutes.

The dissociative state is a therapeutically meaningful aspect of the treatment that helps individuals gain distance from overwhelming emotions.

Ketamine therapy is delivered through several routes, and treatment is personalized based on medical evaluation rather than a one-size-fits-all protocol. Each administration method has different considerations:

• Sublingual tablets: Held in the mouth and absorbed through the oral mucosa, these are delivered at home under medical oversight.
• Subcutaneous injection: Administered with a small insulin-style needle for fast absorption and high bioavailability, available at home through select prescribers.
• IV infusion: Administered in a care setting, offering the highest bioavailability but requiring in-person visits.
• Intranasal (Spravato/esketamine): FDA-approved for treatment-resistant depression and, as of January 2025, as a standalone treatment for major depressive disorder; administered in a certified healthcare setting under a REMS program.

What Is EMDR?

Eye Movement Desensitization and Reprocessing (EMDR) is a protocol-driven psychotherapy developed in the late 1980s to help people process traumatic memories. It uses bilateral stimulation while a client focuses on distressing memories or experiences.

The bilateral stimulation typically involves guided eye movements, but therapists may also use physical tapping or auditory tones. EMDR follows a strict eight-phase protocol.

The therapist guides the client to recall a target memory while simultaneously engaging in the bilateral stimulation. The underlying theory suggests that dual-attention processing helps the brain reprocess the memory so it becomes less emotionally charged over time.

Sessions are typically 60 to 90 minutes long and are conducted in a therapist's office. A standard course often involves six to twelve sessions depending on the complexity of the presenting issue.

EMDR is most extensively studied and widely endorsed for PTSD, with major guidelines recommending it for trauma-related conditions.

The eight phases of EMDR include:

• History taking: The therapist assesses readiness and develops a care plan.
• Preparation: The client learns coping skills and stabilization techniques.
• Assessment: The specific target memory and associated negative beliefs are identified.
• Desensitization: Bilateral stimulation is used while the client focuses on the memory.
• Installation: Positive beliefs are strengthened to replace the negative ones.
• Body scan: The client checks for residual physical tension related to the memory.
• Closure: The therapist ensures the client returns to a state of calm before leaving.
• Reevaluation: The next session begins by checking progress on previously targeted memories.

While EMDR is sometimes applied to anxiety disorders, its guideline endorsements are specific to PTSD and trauma. When evaluating therapeutic options, keep in mind that EMDR's strong PTSD track record does not automatically extend to anxiety-specific applications.

What Does the Published Research Say About EMDR for Anxiety?

When EMDR is evaluated specifically for anxiety disorders rather than PTSD, the research picture changes substantially. The research base for anxiety is smaller, highly fragmented, and methodologically limited compared to the trauma literature.

The Goldstein 2000 Panic-Disorder Finding

Goldstein and colleagues conducted a randomized controlled trial comparing EMDR to a waiting list and to an attention-placebo control (a credible fake therapy designed to match EMDR's structure and time commitment) for panic disorder with agoraphobia.

EMDR was no more effective than the attention-placebo control on any outcome measure. Effect sizes between EMDR and the placebo ranged from d = 0.00 to d = 0.06, meaning the gap between EMDR and the placebo was essentially zero.

The authors concluded that because established effective treatments such as cognitive-behavioral therapy already exist for panic disorder, EMDR should not be the first-line treatment for this condition.

Goldstein 2000 is one of the only placebo-controlled trials of EMDR for any specific anxiety disorder, and no subsequent larger trial has overturned its finding. When EMDR has been tested most rigorously against a credible placebo for an anxiety condition, it showed no measurable advantage.

The Cuijpers 2020 Meta-Analysis Across Mental Health Conditions

A comprehensive meta-analysis (a study that combines and analyzes results across many separate trials) of 76 EMDR trials examined EMDR across multiple mental health conditions to evaluate its broader applicability.⁵ Appearing in Cognitive Behaviour Therapy, this review rigorously assessed the methodological quality of the available literature.

Only four of the 27 studies comparing EMDR to other therapies were considered well-designed enough for their results to be reliable. When the analysis was restricted to those reliable studies, EMDR did not show a meaningful advantage over the other therapies tested.

The authors also noticed that studies showing positive results for EMDR appeared to be getting published more often than studies that did not, a pattern called publication bias. They concluded that there is not enough evidence to advise EMDR for use in other mental health problems beyond short-term PTSD care. This finding does not undercut EMDR's PTSD evidence base. It does mean that the same quality of evidence does not exist for EMDR in anxiety disorders, depression, or other mental health conditions, and the published research on those uses is not strong enough to recommend EMDR as a first-choice treatment for them.⁵

The Composition of the Dedicated EMDR-for-Anxiety Evidence Base

The most prominent dedicated meta-analysis of EMDR specifically for anxiety pooled 17 randomized controlled trials with 647 total participants.⁶ Appearing in the Journal of Psychiatric Research, this review highlights the specific types of anxiety that have actually been studied.

A breakdown of those 17 trials reveals a highly fragmented research landscape:

• 6 trials: specific phobias
• 2 trials: panic disorder
• 3 trials: test anxiety
• 2 trials: communication or public speaking anxiety
• 3 trials: undefined anxiety symptoms
• 1 trial: post-stroke anxiety
• 0 trials: DSM-diagnosed generalized anxiety disorder (GAD)

Only two of the 17 trials were considered well-designed enough for their results to be reliable. The total participant pool across all 17 trials is smaller than many single ketamine studies.

The absence of any GAD-focused trial is notable because generalized anxiety is one of the most common reasons people seek treatment.

What the Published EMDR-for-Anxiety Evidence Does and Does Not Show

Available trial data suggest that EMDR may have some benefit for specific phobias and certain narrow anxiety presentations like test anxiety. It does not show effectiveness for generalized anxiety disorder; the dedicated EMDR-for-anxiety meta-analysis pooled zero trials targeting DSM-diagnosed generalized anxiety disorder.⁶

The overall EMDR-for-anxiety literature is small, limited in quality, and fragmented across different anxiety subtypes. Major medical guidelines recommend EMDR for PTSD, not for anxiety disorders broadly.

The takeaway: EMDR's strong evidence for treating PTSD does not automatically transfer to its use as a treatment for anxiety disorders.

What Does the Published Research Say About Ketamine Therapy for Anxiety?

Ketamine therapy has real-world effectiveness data for anxiety at a highly meaningful scale. Mathai et al. (2024), a real-world, peer-reviewed study of Mindbloom's at-home sublingual ketamine therapy program (n = 11,441 enrolled), provides the largest dataset on this topic to date.⁷

The anxiety-specific findings from this study, which tracked outcomes in real-world clinical care rather than running a randomized experiment, demonstrate substantial symptom reduction across a large population. Participants completed GAD-7 assessments as part of routine care within a supervised at-home protocol.

The results include:

• Sample with baseline GAD-7 data: n = 7,776
• Mean baseline GAD-7 score: 15.2 (moderate-to-severe anxiety)
• Mean GAD-7 at session-4 assessment timepoint: 7.6
• Within-group reduction: 50%
• Response rate (≥50% GAD-7 reduction): 56.1%
• Remission rate (GAD-7 < 5): 28.8%
• Within-group Cohen's d: 1.46 (large effect)
• Symptom deterioration rate: 0.4 percent

Both the scale and the effect magnitude of the Mathai 2024 study stand out within the psychiatric literature. As an observational study, it cannot prove cause and effect with the same certainty as a randomized controlled trial, but it provides real-world data at a scale that no EMDR-for-anxiety study has approached.⁶

Individual results may vary, and outcomes depend on medical factors and engagement with the therapy program.

How Do EMDR and Ketamine Therapy Compare in the Published Anxiety Evidence?

EMDR and ketamine therapy have not been compared head-to-head in a controlled trial for anxiety, so any comparison relies on separate research bases with different designs, populations, and outcome measures.

The comparison must therefore be drawn from their separate bodies of research.

Neither modality has a placebo-controlled prospective trial specifically for generalized anxiety disorder. Where the two evidence bases diverge most sharply is in scale and consistency.

The ketamine dataset includes thousands of participants with validated anxiety measures and a large within-group effect. The EMDR literature is fragmented across small trials of different anxiety subtypes with methodological limitations.

Both modalities have research gaps, but if your primary concern is generalized, persistent anxiety rather than trauma-specific symptoms, the ketamine data addresses that presentation more directly.

Can Ketamine and EMDR Work Together for Anxiety?

Some specialists use ketamine and EMDR in sequence or as complementary treatments to address complex mental health challenges. The combination is sometimes referred to broadly as ketamine-assisted psychotherapy, though the specific pairing of ketamine and EMDR is distinct from standard protocols.

The rationale for combining them is that ketamine's neuroplasticity-enhancing effects may create a window in which EMDR's reprocessing work becomes more accessible. Some practitioners report that clients who feel stuck in traditional EMDR find that ketamine sessions help them engage more deeply with the therapeutic process.

Practical sequencing considerations include:

• Ketamine before EMDR: Providers may use a ketamine session to reduce acute anxiety and open a neuroplastic window, following up with EMDR sessions during that timeframe.
• Parallel use: Other providers run both modalities concurrently as part of a broader, integrated care plan.
• No standardized protocol: There is no published, validated protocol for combining ketamine and EMDR specifically for anxiety. The combination relies entirely on medical judgment rather than a formal body of research.

In theory, combining the two modalities is promising, and some providers actively practice it, but dedicated peer-reviewed research is lacking. The two modalities are not mutually exclusive, and choosing one does not preclude trying the other at a different time.

Is Ketamine Therapy Safe for People With Anxiety?

Ketamine therapy has a well-characterized safety profile based on decades of medical use and extensive peer-reviewed data. In supervised, sub-anesthetic protocols for screened patients, at-home program data report serious adverse events in fewer than 0.1 percent of sessions and common transient effects such as dissociation, nausea, dizziness, sedation, and temporary blood-pressure elevation in about 4 to 5% of sessions.

Safety is a function of medical supervision, thorough screening, and adherence to established protocols.⁸ The main safety considerations relevant to someone with anxiety include:

• Common side effects: Some people experience transient dissociation, perceptual changes, nausea, dizziness, transient elevations in blood pressure, and sedation. As noted above, these occur in approximately 4 to 5% of sessions and typically resolve within hours.
• Serious adverse events: Medical screening and ongoing monitoring are designed to minimize these already rare risks.
• Cardiovascular screening: Ketamine can temporarily increase blood pressure and heart rate. Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is a mandatory part of the intake evaluation.
• Dissociation: As noted earlier, the dissociative state at sub-anesthetic doses is therapeutically meaningful rather than a side effect to avoid. Care protocols include preparation materials and a required peer treatment monitor to support patients through the experience.
• Contraindications: Ketamine therapy may not be appropriate for individuals with psychotic disorders, uncontrolled hypertension, or active substance use disorders. As part of the intake evaluation described above, a licensed provider determines whether ketamine therapy is appropriate for the individual.

Is Ketamine Therapy Addictive?

Abuse and dependence risk in supervised, sub-anesthetic ketamine protocols is low. Ketamine is classified as a Schedule III controlled substance by the DEA, meaning it has accepted medical use and abuse potential that may lead to moderate or low physical dependence or high psychological dependence.

The patterns associated with ketamine misuse, such as frequent unsupervised use or escalating doses in recreational contexts, differ substantially from the supervised, time-limited protocols used in therapeutic settings.⁹ Therapeutic protocols use sub-anesthetic doses on a personalized, provider-guided schedule, not daily or self-directed use.

In at-home ketamine program data, the discontinuation rate due to any concern is just 0.4 percent. If you have a history of substance use disorder, your provider will evaluate whether ketamine therapy is appropriate for you during the screening process.

Are There Safety Considerations With EMDR?

EMDR does not involve medication, but it can temporarily increase emotional distress, vivid dreams, dissociation, or physiological arousal during memory processing, which is why therapist pacing and stabilization are central to safe delivery.

The therapy does involve deliberately engaging with highly distressing memories, which requires careful navigation. The primary considerations involve temporary emotional and physiological activation during the reprocessing work.

The main safety factors include:

• Emotional activation: During and after sessions, some people experience heightened distress, vivid dreams, or emotional sensitivity as the brain reprocesses targeted memories. This is typically temporary and is managed by the therapist through pacing and stabilization techniques.
• Dissociation: Individuals with a history of dissociative responses may experience dissociation during EMDR. Trained EMDR therapists use grounding and resourcing techniques to manage this safely.
• Incomplete processing: If a session ends before a memory is fully reprocessed, the client may feel temporarily more distressed than before the session began. The therapist provides containment strategies for the period between sessions.
• Not appropriate for everyone: EMDR may not be suitable for individuals in acute crisis, those with certain dissociative disorders, or those without adequate stabilization skills.

These considerations are manageable within a competent therapeutic relationship. The key variable in EMDR safety is the therapist's training and judgment in pacing the work appropriately for the client's window of tolerance.

Conclusion

For anxiety disorders specifically, the published evidence base for EMDR is limited. The only placebo-controlled RCT of EMDR for a specific anxiety disorder (panic disorder with agoraphobia) returned a null finding against an attention-placebo control. A comprehensive 76-trial meta-analysis of EMDR concluded that the published research is not yet strong enough to recommend EMDR for anxiety or related mental health conditions. And the dedicated EMDR-for-anxiety meta-analysis pooled zero trials targeting DSM-diagnosed generalized anxiety disorder.

Ketamine therapy has a different evidence profile for anxiety. The largest published dataset reporting on anxiety outcomes comes from a real-world effectiveness study of more than 7,700 patients with baseline GAD-7 anxiety, showing a 50 percent within-group reduction in anxiety scores. That dataset is observational rather than placebo-controlled, but it is substantially larger than the entire pooled EMDR-for-anxiety literature.

The asymmetry between these two evidence bases is most directly relevant for people whose primary concern is generalized, persistent anxiety, which is the presentation the published ketamine therapy data addresses most directly. Decisions between modalities, including whether either or both may be appropriate for a given individual, should involve a licensed provider who can assess history, current symptoms, medications, and treatment goals.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.